{"entity":{"id":"nct05053971","kind":"trial","name":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","aka":[],"tldr":"A phase 1/2 trial in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","summary":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors is a phase 1/2, interventional study registered as NCT05053971 by National Cancer Institute (NCI), with a registry enrolment figure of 49 participants, started 2022-11-16 and due to reach its primary completion in 2027-07-01. Interventions recorded: BET Bromodomain Inhibitor ZEN-3694; Computed Tomography; Core Biopsy; Entinostat. Conditions listed: Advanced Malignant Solid Neoplasm; Locally Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma. Primary outcome: Maximum tolerated dose (MTD) (Phase Ib); Recommended phase 2 dose (RP2D) (Phase Ib); Objective response rate (ORR) (Phase II). Pancreatic eligibility wording from the registry: \"* For patients in Phase 2: Patients must have locally advanced, unresectable OR metastatic pancreatic cancer refractory to standard therapy\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05053971","url":"https://clinicaltrials.gov/study/NCT05053971"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05053971","phase":"1/2","setting":"Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors","sponsor":"National Cancer Institute (NCI)","enrolled":49,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05053971/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}